{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T08:33:21Z","timestamp":1768552401304,"version":"3.49.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,30]]},"DOI":"10.7759\/cureus.63518","type":"journal-article","created":{"date-parts":[[2024,6,30]],"date-time":"2024-06-30T15:47:13Z","timestamp":1719762433000},"source":"Crossref","is-referenced-by-count":1,"title":["Antifibrotics in the Management of Rheumatoid Arthritis-Associated Interstitial Lung Disease: Prospective Real-World Experience From an Interstitial Lung Disease Clinic in India"],"prefix":"10.7759","author":[{"given":"Ajoy K","family":"Behera","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vikas","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pratibha","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ranganath","family":"Ganga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jhasaketan","family":"Meher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saroj","family":"Pati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kulshreshth","family":"Sinha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa836","article-title":"Prevalence, incidence and cause-specific mortality of rheumatoid arthritis-associated interstitial lung disease among older rheumatoid arthritis patients","volume":"60","author":"Sparks JA","year":"2021","unstructured":"Sparks JA, Jin Y, Cho SK, Vine S, Desai R, Doyle TJ, Kim SC. Prevalence, incidence and cause-specific mortality of rheumatoid arthritis-associated interstitial lung disease among older rheumatoid arthritis patients. Rheumatology. 2021, 60:3689-98. 10.1093\/rheumatology\/keaa836","journal-title":"Rheumatology"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/art.27405","article-title":"Incidence and mortality of interstitial lung disease in rheumatoid arthritis: A population-based study","volume":"62","author":"Bongartz T","year":"2010","unstructured":"Bongartz T, Nannini C, Medina-Velasquez YF, et al.. Incidence and mortality of interstitial lung disease in rheumatoid arthritis: A population-based study. Arthritis Rheum. 2010, 62:1583-91. 10.1002\/art.27405","journal-title":"Arthritis Rheum"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-028466","article-title":"Is incident rheumatoid arthritis interstitial lung disease associated with methotrexate treatment? Results from a multivariate analysis in the ERAS and ERAN inception cohorts","volume":"9","author":"Kiely P","year":"2019","unstructured":"Kiely P, Busby AD, Nikiphorou E, et al.. Is incident rheumatoid arthritis interstitial lung disease associated with methotrexate treatment? Results from a multivariate analysis in the ERAS and ERAN inception cohorts. BMJ Open. 2019, 9:e028466. 10.1136\/bmjopen-2018-028466","journal-title":"BMJ Open"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X221074457","article-title":"The role of antifibrotics in the treatment of rheumatoid arthritis-associated interstitial lung disease","volume":"14","author":"Liang M","year":"2022","unstructured":"Liang M, Matteson EL, Abril A, Distler JH. The role of antifibrotics in the treatment of rheumatoid arthritis-associated interstitial lung disease. Ther Adv Musculoskelet Dis. 2022, 14:10.1177\/1759720X221074457","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000703","article-title":"Management issues in rheumatoid arthritis-associated interstitial lung disease","volume":"32","author":"England BR","year":"2020","unstructured":"England BR, Hershberger D. Management issues in rheumatoid arthritis-associated interstitial lung disease. Curr Opin Rheumatol. 2020, 32:255-63. 10.1097\/BOR.0000000000000703","journal-title":"Curr Opin Rheumatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10173806","article-title":"Decision-making strategy for the treatment of rheumatoid arthritis-associated interstitial lung disease (RA-ILD)","volume":"10","author":"Yamakawa H","year":"2021","unstructured":"Yamakawa H, Ogura T, Kameda H, Kishaba T, Iwasawa T, Takemura T, Kuwano K. Decision-making strategy for the treatment of rheumatoid arthritis-associated interstitial lung disease (RA-ILD). J Clin Med. 2021, 10:3806. 10.3390\/jcm10173806","journal-title":"J Clin Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.743977","article-title":"Management of progressive fibrosing interstitial lung diseases (PF-ILD)","volume":"8","author":"Copeland CR","year":"2021","unstructured":"Copeland CR, Lancaster LH. Management of progressive fibrosing interstitial lung diseases (PF-ILD). Front Med. 2021, 8:743977. 10.3389\/fmed.2021.743977","journal-title":"Front Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2019.04.005","article-title":"Impact of the pattern of interstitial lung disease on mortality in rheumatoid arthritis: A systematic literature review and meta-analysis","volume":"49","author":"Singh N","year":"2019","unstructured":"Singh N, Varghese J, England BR, et al.. Impact of the pattern of interstitial lung disease on mortality in rheumatoid arthritis: A systematic literature review and meta-analysis. Semin Arthritis Rheum. 2019, 49:358-65. 10.1016\/j.semarthrit.2019.04.005","journal-title":"Semin Arthritis Rheum"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac184","article-title":"Automated quantification system predicts survival in rheumatoid arthritis-associated interstitial lung disease","volume":"61","author":"Oh JH","year":"2022","unstructured":"Oh JH, Kim GH, Cross G, Barnett J, Jacob J, Hong S, Song JW. Automated quantification system predicts survival in rheumatoid arthritis-associated interstitial lung disease. Rheumatology. 2022, 61:4702-10. 10.1093\/rheumatology\/keac184","journal-title":"Rheumatology"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30036-9","article-title":"Nintedanib in patients with progressive fibrosing interstitial lung diseases\u2014subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: A randomised, double-blind, placebo-controlled, parallel-group trial","volume":"8","author":"Wells AU","year":"2020","unstructured":"Wells AU, Flaherty KR, Brown KK, et al.. Nintedanib in patients with progressive fibrosing interstitial lung diseases\u2014subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: A randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Respir Med. 2020, 8:453-60. 10.1016\/S2213-2600(20)30036-9","journal-title":"Lancet Respir Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1186\/s12890-021-01783-1","article-title":"Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: A systematic review and meta-analysis","volume":"21","author":"Finnerty JP","year":"2021","unstructured":"Finnerty JP, Ponnuswamy A, Dutta P, Abdelaziz A, Kamil H. Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: A systematic review and meta-analysis. BMC Pulm Med. 2021, 21:411. 10.1186\/s12890-021-01783-1","journal-title":"BMC Pulm Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(22)00260-0","article-title":"Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: A randomised, double-blind, placebo-controlled, phase 2 study","volume":"11","author":"Solomon JJ","year":"2023","unstructured":"Solomon JJ, Danoff SK, Woodhead FA, et al.. Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: A randomised, double-blind, placebo-controlled, phase 2 study. Lancet Respir Med. 2023, 11:87-96. 10.1016\/S2213-2600(22)00260-0","journal-title":"Lancet Respir Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201908-1590ST","article-title":"Standardization of Spirometry 2019 Update. An Official American Thoracic Society and European Respiratory Society Technical Statement","volume":"200","author":"Graham BL","year":"2019","unstructured":"Graham BL, Steenbruggen I, Miller MR, et al.. Standardization of Spirometry 2019 Update. An Official American Thoracic Society and European Respiratory Society Technical Statement. Am J Respir Crit Care Med. 2019, 200:e70-88. 10.1164\/rccm.201908-1590ST","journal-title":"Am J Respir Crit Care Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.166.1.at1102","article-title":"ATS statement: Guidelines for the six-minute walk test","volume":"166","year":"2002","unstructured":"ATS statement. Guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002, 166:111-7. 10.1164\/ajrccm.166.1.at1102","journal-title":"Am J Respir Crit Care Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2018-000363","article-title":"The King's Brief Interstitial Lung Disease (KBILD) questionnaire: An updated minimal clinically important difference","volume":"6","author":"Sinha A","year":"2019","unstructured":"Sinha A, Patel AS, Siegert RJ, et al.. The King's Brief Interstitial Lung Disease (KBILD) questionnaire: An updated minimal clinically important difference. BMJ Open Respir Res. 2019, 6:e000363. 10.1136\/bmjresp-2018-000363","journal-title":"BMJ Open Respir Res"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.05.00035005","article-title":"Standardisation of the measurement of lung volumes","volume":"26","author":"Wanger J","year":"2005","unstructured":"Wanger J, Clausen JL, Coates A, et al.. Standardisation of the measurement of lung volumes. Eur Respir J. 2005, 26:511-22. 10.1183\/09031936.05.00035005","journal-title":"Eur Respir J"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202202-0399ST","article-title":"Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: An official ATS\/ERS\/JRS\/ALAT clinical practice guideline","volume":"205","author":"Raghu G","year":"2022","unstructured":"Raghu G, Remy-Jardin M, Richeldi L, et al.. Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: An official ATS\/ERS\/JRS\/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2022, 205:e18-47. 10.1164\/rccm.202202-0399ST","journal-title":"Am J Respir Crit Care Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead027","article-title":"Lung function trajectory of rheumatoid arthritis-associated interstitial lung disease","volume":"62","author":"Chang SH","year":"2023","unstructured":"Chang SH, Lee JS, Ha YJ, et al.. Lung function trajectory of rheumatoid arthritis-associated interstitial lung disease. Rheumatology. 2023, 62:3014-24. 10.1093\/rheumatology\/kead027","journal-title":"Rheumatology"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.156.2.9609016","article-title":"Interstitial lung disease in recent onset rheumatoid arthritis","volume":"156","author":"Gabbay E","year":"1997","unstructured":"Gabbay E, Tarala R, Will R, Carroll G, Adler B, Cameron D, Lake FR. Interstitial lung disease in recent onset rheumatoid arthritis. Am J Respir Crit Care Med. 1997, 156:528-35. 10.1164\/ajrccm.156.2.9609016","journal-title":"Am J Respir Crit Care Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.5005\/japi-11001-0195","article-title":"Pulmonary manifestations in patients of rheumatoid arthritis and its correlation with severity of disease","volume":"71","author":"Gauri LA","year":"2023","unstructured":"Gauri LA, Sharma B, Bhatnagar K, et al.. Pulmonary manifestations in patients of rheumatoid arthritis and its correlation with severity of disease. J Assoc Physicians India. 2023, 71:11-2. 10.5005\/japi-11001-0195","journal-title":"J Assoc Physicians India"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.reumae.2021.07.002","article-title":"Screening of interstitial lung disease in patients with rheumatoid arthritis: A systematic review. (Article in Spanish)","volume":"18","author":"Garrote-Corral S","year":"2022","unstructured":"Garrote-Corral S, Silva-Fern\u00e1ndez L, Seoane-Mato D, et al.. Screening of interstitial lung disease in patients with rheumatoid arthritis: A systematic review. (Article in Spanish). Reumatol Clin (Engl Ed). 2022, 18:587-96. 10.1016\/j.reumae.2021.07.002","journal-title":"Reumatol Clin (Engl Ed)"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1067\/j.cpradiol.2009.06.002","article-title":"Rheumatoid arthritis: Spectrum of computed tomographic findings in pulmonary diseases","volume":"39","author":"Manjunatha YC","year":"2010","unstructured":"Manjunatha YC, Seith A, Kandpal H, Das CJ. Rheumatoid arthritis: Spectrum of computed tomographic findings in pulmonary diseases. Curr Probl Diagn Radiol. 2010, 39:235-46. 10.1067\/j.cpradiol.2009.06.002","journal-title":"Curr Probl Diagn Radiol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1002\/hsr2.1449","article-title":"Expectations, symptoms, and quality of life before and after 1 year of Pirfenidone treatment in patients with idiopathic pulmonary fibrosis: A single-arm, open-label nonrandomized study","volume":"6","author":"Jastrz\u0119bski D","year":"2023","unstructured":"Jastrz\u0119bski D, Kostorz-Nosal S, Galle D, et al.. Expectations, symptoms, and quality of life before and after 1 year of Pirfenidone treatment in patients with idiopathic pulmonary fibrosis: A single-arm, open-label nonrandomized study. Health Sci Rep. 2023, 6:e1449. 10.1002\/hsr2.1449","journal-title":"Health Sci Rep"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/253178-antifibrotics-in-the-management-of-rheumatoid-arthritis-associated-interstitial-lung-disease-prospective-real-world-experience-from-an-interstitial-lung-disease-clinic-in-india","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,30]],"date-time":"2024-06-30T15:47:17Z","timestamp":1719762437000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/253178-antifibrotics-in-the-management-of-rheumatoid-arthritis-associated-interstitial-lung-disease-prospective-real-world-experience-from-an-interstitial-lung-disease-clinic-in-india"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,30]]},"references-count":23,"URL":"https:\/\/doi.org\/10.7759\/cureus.63518","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6,30]]}}}